Absorption and metabolism characteristics of pristimerin as determined by a sensitive and reliable LC-MS/MS method

Abstract

In this research, a sensitive and reliable LC-MS/MS method was developed and applied to determine the concentration of pristimerin in rat plasma, cell incubation media and metabolism incubation mixtures. The absolute oral bioavailability of pristimerin is 28.4% at a dose of 1 mg·kg(-1), and the bioavailability was poor. The bidirectional transport of pristimerin across Caco-2 cells was studied in vitro. A markedly higher transport of pristimerin across Caco-2 cells was observed in the basolateral-to-apical direction and was abrogated in the presence of the P-gp inhibitor, verapamil. The result indicated that P-gp might be involved in the transport of pristimerin in intestine. The phase I and phase II metabolic stability was also investigated using human liver microsomes (HLM) and S9 fractions, respectively. Pristimerin was stable in S9 fractions but metabolized in HLM with a half-life of 20.4 min, which indicated that pristimerin could be mainly metabolized by phase I enzymes. In conclusion, the absolute oral bioavailability of pristimerin in plasma, transport across Caco-2 cell monolayers, and metabolic stability in HLM and S9 fractions were systematically investigated by using a sensitive and reliable LC-MS/MS method.

Keywords: Caco-2 cells; Glucose 6-phosphate (PubChem CID: 5958); Human liver microsomes; Hydrocortisone (PubChem CID: 5754); Lucifer yellow (PubChem CID: 93367); P-gp; Pharmacokinetics; Pristimerin; Pristimerin (PubChem CID: 159516); UDPGA (PubChem CID: 17473); Verapamil (PubChem CID: 62969); β-nicotinamide adenine dinucleotide phosphate (PubChem CID: 5884).